B.Riley Downgrades Ambrx Biopharma (AMAM) to Neutral

B.Riley analyst Yuan Zhi downgraded Ambrx Biopharma (NASDAQ: AMAM) from Buy to Neutral with a price target of $28.00 (from $26.00).

For an analyst ratings summary and ratings history on Ambrx Biopharma click here. For more ratings news on Ambrx Biopharma click here.

Shares of Ambrx Biopharma closed at $13.63 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
• Chemtrade Logistics Income Fund (CHE-U:CN) (CGIFF) PT Raised to Cdn$18.50 at Desjardins